{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:17:10Z","timestamp":1791515830106,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ejmech.2022.114810","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T21:40:53Z","timestamp":1664833253000},"page":"114810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor"],"prefix":"10.1016","volume":"244","author":[{"given":"Haixia","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianglong","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chencen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaowei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShuTing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuBao","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heqiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8403-0236","authenticated-orcid":false,"given":"Qianqian","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114810_bib1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114810_bib2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","article-title":"The BCR-ABL story: bench to bedside and back","volume":"22","author":"Wong","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2022.114810_bib3","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","article-title":"An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity","volume":"37","author":"Konopka","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114810_bib4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2022.114810_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10147-013-0641-7","article-title":"Ever-advancing chronic myeloid leukemia treatment","volume":"19","author":"Kimura","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2022.114810_bib6","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s12185-021-03126-6","article-title":"Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"113","author":"Lee","year":"2021","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.ejmech.2022.114810_bib7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-021-01662-3","article-title":"Asciminib: first approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114810_bib8","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114810_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14010215","article-title":"BCR-ABL1 tyrosine kinase complex signaling transduction: challenges to overcome resistance in chronic myeloid leukemia","volume":"14","author":"Amarante-Mendes","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2022.114810_bib10","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114810_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114442","article-title":"The progress of small-molecules and degraders against BCR-ABL for the treatment of CML","volume":"238","author":"Pan","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114810_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.696960","article-title":"Pharmacogenomics of impaired tyrosine kinase inhibitor response: lessons learned from chronic myelogenous leukemia","volume":"12","author":"Kaehler","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114810_bib13","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.hoc.2011.09.005","article-title":"BCR-ABL mutations in chronic myeloid leukemia","volume":"25","author":"Ernst","year":"2011","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.ejmech.2022.114810_bib14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/cbdd.13801","article-title":"Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation","volume":"97","author":"Liu","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2022.114810_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/fon-2018-0371","article-title":"Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia","volume":"15","author":"Pavlovsky","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejmech.2022.114810_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2022.114810_bib17","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114810_bib18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2022.114810_bib19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00277-015-2539-0","article-title":"Detection of BCR-ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencing","volume":"95","author":"Szankasi","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejmech.2022.114810_bib20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.5966\/sctm.2012-0159","article-title":"Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors","volume":"3","author":"Ichim","year":"2014","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.ejmech.2022.114810_bib21","series-title":"PROTACs: Past, Present and Future","author":"Li","year":"2022"},{"key":"10.1016\/j.ejmech.2022.114810_bib22","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2022.114810_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/d41573-021-00052-4","article-title":"Targeted protein degraders crowd into the clinic","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114810_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.692574","article-title":"PROTAC: an effective targeted protein degradation strategy for cancer therapy","volume":"12","author":"Qi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114810_bib25","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.cell.2020.10.038","article-title":"Mapping the degradable kinome provides a resource for expedited degrader development","volume":"183","author":"Donovan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114810_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.685106","article-title":"Opportunities and challenges of small molecule induced targeted protein degradation","volume":"9","author":"He","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2022.114810_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.coph.2021.02.009","article-title":"Transforming targeted cancer therapy with PROTACs: a forward-looking perspective","volume":"57","author":"Farnaby","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114810_bib28","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A potent and highly small-molecule degrader of STAT3 achieves complete tumor regression in vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2022.114810_bib29","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC design for the degradation of oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2022.114810_bib30","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/cas.13284","article-title":"Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands","volume":"108","author":"Shibata","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2022.114810_bib31","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1021\/acs.jmedchem.9b02058","article-title":"Azo-PROTAC: novel light-controlled small-molecule tool for protein knockdown","volume":"63","author":"Jin","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114810_bib32","doi-asserted-by":"crossref","first-page":"9281","DOI":"10.1021\/acs.jmedchem.9b01264","article-title":"Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting von hippel-lindau (VHL) E3 ubiquitin ligase","volume":"62","author":"Zhao","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114810_bib33","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1021\/acs.jmedchem.0c00967","article-title":"Global PROTAC toolbox for degrading BCR-ABL overcomes drug-resistant mutants and adverse effects","volume":"63","author":"Yang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114810_bib34","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.apsb.2020.11.009","article-title":"Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2022.114810_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113645","article-title":"Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation","volume":"223","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114810_bib36","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1021\/acsmedchemlett.7b00247","article-title":"Targeting the allosteric site of oncoprotein BCR-ABL as an alternative strategy for effective target protein degradation","volume":"8","author":"Shimokawa","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114810_bib37","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-19-1236","article-title":"Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation","volume":"79","author":"Burslem","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114810_bib38","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1039\/D0CC02201B","article-title":"Scaffold hopping enables direct access to more potent PROTACs with in vivo activity","volume":"56","author":"Burslem","year":"2020","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2022.114810_bib39","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114810_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201900376","article-title":"Design and synthesis of new lenalidomide analogs via Suzuki cross-coupling reaction","volume":"353","author":"Xiao","year":"2020","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.ejmech.2022.114810_bib41","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ejmech.2019.05.035","article-title":"Design, synthesis and biological evaluation of the thioether-containing lenalidomide analogs with anti-proliferative activities","volume":"176","author":"Xiao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114810_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112912","article-title":"Design, synthesis and biological evaluation of thioether-containing lenalidomide and pomalidomide derivatives with anti-multiple myeloma activity","volume":"209","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114810_bib43","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1021\/jm401375q","article-title":"Data-mining for sulfur and fluorine: an evaluation of pharmaceuticals to reveal opportunities for drug design and discovery","volume":"57","author":"Ilardi","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114810_bib44","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","article-title":"gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS","volume":"17","author":"Vald\u00e9s-Tresanco","year":"2021","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2022.114810_bib45","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s42003-018-0105-8","article-title":"Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance","volume":"1","author":"Salami","year":"2018","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejmech.2022.114810_bib46","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114810_bib47","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41589-018-0055-y","article-title":"Plasticity in binding confers selectivity in ligand-induced protein degradation","volume":"14","author":"Nowak","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114810_bib48","doi-asserted-by":"crossref","first-page":"E7285","DOI":"10.1073\/pnas.1803662115","article-title":"Delineating the role of cooperativity in the design of potent PROTACs for BTK","volume":"115","author":"Zorba","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2022.114810_bib49","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40364-020-0182-y","article-title":"Novel immunomodulatory drugs and neo-substrates","volume":"8","author":"Gao","year":"2020","journal-title":"Biomark Res."},{"key":"10.1016\/j.ejmech.2022.114810_bib50","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41422-021-00533-6","article-title":"Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently","volume":"31","author":"Yang","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2022.114810_bib51","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00277-018-3284-y","article-title":"Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies","volume":"97","author":"Chen","year":"2018","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejmech.2022.114810_bib52","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jmgm.2019.03.018","article-title":"Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL","volume":"89","author":"Zhan","year":"2019","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.ejmech.2022.114810_bib53","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.leukres.2018.10.019","article-title":"Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemia","volume":"76","author":"Kang","year":"2019","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2022.114810_bib65","doi-asserted-by":"crossref","first-page":"113328","DOI":"10.1016\/j.ejmech.2021.113328","article-title":"Effective degradation of EGFR(L858R+T790M) mutant proteins by CRBN-based PROTACs through both proteosome and autophagy\/lysosome degradation systems","volume":"218","author":"Qu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114810_bib66","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1021\/acs.orglett.9b01326","article-title":"Chemoselective synthesis of lenalidomide-based PROTAC library using alkylation reaction","volume":"21","author":"Qiu","year":"2019","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2022.114810_bib54","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/jcc.21409","article-title":"Exploring hierarchical refinement techniques for induced fit docking with protein and ligand flexibility","volume":"31","author":"Borrelli","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2022.114810_bib55","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1021\/ct500189s","article-title":"Leveraging data fusion strategies in multireceptor lead optimization MM\/GBSA end-point methods","volume":"10","author":"Knight","year":"2014","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2022.114810_bib56","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/prot.23106","article-title":"The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling","volume":"79","author":"Li","year":"2011","journal-title":"Proteins"},{"key":"10.1016\/j.ejmech.2022.114810_bib57","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/prot.22711","article-title":"Improved side-chain torsion potentials for the Amber ff99SB protein force field","volume":"78","author":"Lindorff-Larsen","year":"2010","journal-title":"Proteins"},{"key":"10.1016\/j.ejmech.2022.114810_bib58","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jmgm.2005.12.005","article-title":"Automatic atom type and bond type perception in molecular mechanical calculations","volume":"25","author":"Wang","year":"2006","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.ejmech.2022.114810_bib59","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2022.114810_bib60","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/1756-0500-5-367","article-title":"Acpype - AnteChamber PYthon parser interfacE","volume":"5","author":"Sousa da Silva","year":"2012","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.ejmech.2022.114810_bib61","first-page":"5068","article-title":"From proteins to perturbed Hamiltonians: a suite of tutorials for the GROMACS-2018 molecular simulation package [article v1.0]","volume":"1","author":"Lemkul","year":"2018","journal-title":"Liv. J. Comput. Molec. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422007127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422007127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:54:38Z","timestamp":1759330478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422007127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":63,"alternative-id":["S0223523422007127"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114810","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114810","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114810"}}